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Background: Acanthamoeba keratitis (AK) is a sight-threatening infectious disease. Its effective and safe med-
ical therapy remains highly debated. Recently, voriconazole, a monotriazole with noted in vitro activity against a
large variety of fungi, has been successfully used both topically and systemically to treat human AK cases.
Objectives: To measure anti-Acanthamoeba polyphaga in vitro activity, anti-rat AK efficiency and rat cornea
penetration of eye-drop and oral voriconazole.
Methods: A. polyphaga was maintained in axenic cultures. In vitro, amoebicidal and cysticidal activities of vori-
conazole were measured using an XTT assay. AK lesions of Sprague Dawley rats were scored from grade 0 to
grade 3. For 21days, from day 7 post-infection, voriconazole (1% solution) eye drops were instilled or voricon-
azole was administered by gavage (60mg/kg/day). After killing, superficial corneal epithelium scrapings were
cultured and analysed by PCR, and eye-globe histology was performed. Cornea and plasma concentrations were
determined using 2D HPLC separation and tandemMS.
Results: In vitro, voriconazole inhibited trophozoite proliferation with an IC50 value of 0.02mg/L and an IC90
value of 2.86mg/L; no cysticidal effect was found. In AK rats, eye drops reduced clinical worsening from day 7 to
day 14 post-infection and oral voriconazole was not effective. Voriconazole cornea concentrations were directly
dependent on the frequency of eye-drop instillations, which resulted in lower plasma concentrations, whilst oral
voriconazole resulted in lower cornea concentrations.
Conclusions: Present data underline the need for high-frequency eye-drop instillation regimens for efficient
AK therapy.
Introduction
Although its occurrence is low, human Acanthamoeba keratitis
(AK) is a severe, sight-threatening condition, often associated with
contact-lens wearing, with a substantial proportion of patients
requiring further optical or therapeutic keratoplasty or enucleation.
Acanthamoeba castellanii and Acanthamoeba polyphaga are the
most common species to cause keratitis.1 The efficacy and safety
of currently available medical treatments are highly debated.
Biguanides are commonly used as first-line treatment, with poly-
hexamethylenebiguanide (PHMB) and chlorhexidine previously es-
tablished as the most successful cysticidal agents in vitro.2
Recently, voriconazole, a monotriazole with noted in vitro activity
against a large variety of fungi, has been successfully used both
topically and systemically in human AK cases.3–5 The aim of this
study was to measure anti-A. polyphaga in vitro activity, anti-rat
AK efficiency and rat cornea penetration of topical and oral
voriconazole.
Materials and methods
Acanthamoeba
From axenic A. polyphaga cultures (isolate ATCC 50495, Rockville, MD, USA)
grown at 30C in 20 cm2 flasks in Peptone Yeast Extract Glucose Broth (PYG)
C
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medium, 80% trophozoite suspensions were obtained by refrigerating
flasks in ice-water baths. To obtain encystment, washed trophozoites were
resuspended in high salt encystment medium (250mM NaCl, 4.6mM
MgSO4 and 0.36mMCaCl2) as previously described.
6
Voriconazole preparations
Voriconazole solutions were prepared with sterile injection water using
10mg/mL (1% w/v) intravenous voriconazole lyophilisate (Vfend, Pfizer,
Paris, France) for in vitro studies and eye drops and 200mg Vfend tablets
for oral treatment.
In vitro evaluation of voriconazole amoebicidal and
cysticidal activities
Trophozoites (103/100lL/well) were allowed to adhere to 96-well flat-
bottom microplates (2h, 37C) and voriconazole was added for 72h (final
concentrations of 0.01, 0.05, 0.1, 0.5, 1, 2, 5, 20 and 40mg/L). Trophozoite
viability was measured using an XTT assay (Sigma-Aldrich, Saint-Quentin-
Fallavier, France) (final concentration of 0.3mg/mL, incubation for 6–24h
at 37C). After subtracting the 630nm absorbance value from correspond-
ing 490nm values, for wavelength correction of optical defects, results
were expressed as the percentage of control (medium alone) culture well
values. To evaluate cysticidal activity, voriconazole was added for 24 or
48h (final concentrations of 5, 10, 50, 100 and 200mg/L) in microplates
containing 103 cysts/100lL/well and maintained at 37C for 5days, i.e.
until .80% trophozoite confluence in control wells. Trophozoite reversion
was evaluated using XTT colorimetry after incubation for 2, 4 or 6h at 37C
and absorbance reading and correction as above. In control wells, .90%
trophozoite reversionwasmicroscopically verified.
Experimental A. polyphaga rat keratitis and
voriconazole treatment
All procedures were performed according to regulations of the French
Ministry of Research after approval of the ad hoc Ethics Committee (No.
00755.02). In 150g male Sprague Dawley specific-pathogen-free rats
(Janvier, Le Genest-Saint-Isle, France), housed two per cage, AK was ob-
tained as described.7 Eyes were examined weekly using a slit lamp by the
same experienced investigator and keratitis lesions were scored. The fol-
lowing grade scheme was used: grade 0, no corneal opacity; grade 1, cor-
neal opacity visible only using oblique slit beam; grade 2, corneal opacity
visible using retro-illumination but not sufficient to obscure iris details; or
grade 3, corneal opacity visible using retro-illumination and obscuring iris
details.8,9 Nineteen ratswith left eye AK received voriconazole (1% solution)
eye dropsdaily for 21days in both eyes. Instillation sequences are summar-
ized in Table 1. Orally treated AK rats received voriconazole by gavage
(60mg/kg/day, two daily doses).
Ophthalmic microbiological analyses and histology
On day 28 post-infection (p.i.), the rats were euthanized, blood samples
were collected and superficial corneal epithelium scrapings were obtained
for cultures (non-nutrient agar plates with Escherichia coli suspension over-
lay, examined for viable Acanthamoeba every week for 1month).
Acanthamoeba spp. quantitative PCR was performed in a Light Cycler 2.0
(Roche Diagnostics), using primers and probe as described by Qvarnstrom
et al.10 The reaction mix contained 1% FastStart DNA master mix (Roche
Diagnostics, Meylan, France), 0.2lM primers, 0.2lM probe, 3.5mM MgCl2
and 10lL of DNA in a total reaction volume of 25lL. Cycling parameters
were 10min at 95C followed by45 cycles of 15s at 95C and 30 s at 63C.
Eye globes of killed animals were punctured, placed in a 10% buffered
formaldehyde solution and paraffin-embedded and 3mm sections were
stainedwith haematoxylin–eosin.
Cornea and plasma voriconazole concentrations during
topical and oral treatments in AK rats
At the end of each instillation regimen as above, right (non-infected) cornea
samples were thawed and weighed, and 100lL of voriconazole-d5-
surchargedmethanol (internal standard) was added to each sample as an
extraction/precipitation reagent. After vortex-mixing, tubeswere incubated
for 30min at room temperature and sonicated for 15min before centrifu-
gation (16000g for 5min). For plasma samples, each 50lL aliquot was
mixed with 100lL of extraction/precipitation reagent, vortex-mixed and
centrifuged in a like manner. Supernatants were transferred to HPLC vials
and 1lL was injected for quantification in a 2D HPLC separation and tan-
dem MS system consisting of a 3200 QTRAP tandem mass spectrometer
equipped with a TurboIonSpray source (AB Sciex, Framingham, USA).
Sample clean-upwas carried out online in a perfusion column preceding an
analytical octadecyl column connected to the mass spectrometer.
Quantification was performed by multiple reaction monitoring (MRM) in
positive ionmodewith voriconazole-d5 as the internal standard. The assay,
conducted in accordancewith US FDA bioanalytical guidelines,11 resulted in
lower and upper quantification thresholds of 0.005 and 0.01lg/mL, re-
spectively, for both cornea and plasma samples.
Data analysis
Statistics were performed using contingency analysis (Fisher’s exact tests).
A P value,0.05was considered significant.
Table 1. Rat instillation sequences of 1% voriconazole eye drops and voriconazole cornea concentration measured in the right non-infected cornea
Voriconazole eye-drop regimen
Voriconazole cornea concentration
(last day of eye-drop sequences),
mean+ SD
first instillation sequence (frequency/
duration)
subsequent instillation sequence
(frequency/duration)
hourly (13 times a day, 8 am to 8 pm)/
3 days
none 5.6+4.4 ng/mg (5 rats) (day 10 p.i.)
hourly (13 times a day, 8 am to 8 pm)/
3 days
every 2 h (7 times a day, 8 am to 8 pm)/ 11 days 2.38+1.6 ng/mg (5 rats) (day 17 p.i.)
hourly (13 times a day, 8 am to 8 pm)/
3 days
every 2 h (7 times a day, 8 am to 8 pm)/11 days
then every 4h (4 times a day, 8 am to 8 pm)/
7 days
0.32+0.15 ng/mg (9 rats) (day 28 p.i.)
p.i., post-infection.
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Results
In vitro voriconazole amoebicidal activity
Optimal XTT staining to evaluate trophozoite viability was obtained
after 24h incubation (datanot shown). In three triplicated independ-
ent experiments, voriconazole inhibited trophozoite proliferation in a
concentration-dependent manner; incubation with 0.01, 0.05, 0.1,
0.5, 1, 2, 5, 20 and 40mg/L voriconazole resulted in inhibition per-
centages of 44.4+1.3, 55.3+3.5, 67.9+22.5, 81.6+26.0, 77.5+10.3,
93.5+3.1, 98.6+1.4, 96.6+4.5 and 100+0.7 (mean+ SD), respect-
ively, corresponding to an average IC50 value of 0.02mg/L and
an average IC90 value of 2.86mg/L. After cyst incubation with 5, 10,
50, 100 and 200mg/L voriconazole for 24 or 48h, reversion to
trophozoites was similar to that of untreated controls (.90%,
P.0.05).
Voriconazole efficacy against A. polyphaga rat keratitis
As shown in Table 2, worsening of clinical symptoms fromday 7 to
day 14 p.i. was observed in fewer rats in the eye-drop group (topic-
ally treatedwith 1% voriconazole from day 7 to day 28 p.i.) than in
the untreated control group (P"0.001), and clinical infection simi-
larly worsened in both groups from day 14 to day 28 p.i. (P.0.05).
In orally treated rats, worsening of clinical infection was similar to
that of untreated controls from day 7 to day 28 p.i. (P.0.05).
Topical or oral voriconazole did not affect day 28 p.i. culture, PCR or
histology positivities for A. polyphaga (Table S1, available as
Supplementary data at JACOnline).
Cornea and plasma voriconazole concentrations in AK
rats treated with eye drops and oral voriconazole
As shown in Table 1, voriconazole cornea concentrations were dir-
ectly dependent on the frequency of eye-drop instillations.
Voriconazole cornea concentrations were higher after topical ad-
ministration hourly and every 2h than after administration every
4h (P"0.005, respectively). Following oral twice-a-day adminis-
tration of 60mg/kg/day for 21days, mean cornea and plasma
voriconazole concentrations averaged 1.72+1.79ng/mg (as ng/lL
cornea, considering that 90% of cornea tissue is composed of
water)12 and3.29+2.27mg/L in 10 rats (mean+ SD), respectively.
Discussion
The voriconazole Acanthamoeba IC90 evaluation (2.86mg/L) in
this study compares with previously reported values of
1–52.85mg/L and strong inhibition observed over 40mg/L.13,14
No cysticidal activity was detected, consistent with the reported
cyst resistance of clinical isolates at 1 and 10mg/L concentra-
tions.15 In other discrepant studies, however, cysticidal activity
was obtained at 5–15mg/L or at higher concentrations for collec-
tion strains and clinical isolates, respectively.16,17 Differences in
Acanthamoeba strains and methodologies (such as staining) may
account for such variations.
In an AK rat model, topical and oral voriconazole doses were
determined according to previous studies in humans.18 Eye-drop
treatment from day 7 p.i. reduced AK lesion worsening from day
7 to day 14 p.i. without later effects, whereas oral voriconazole
therapy did not modify clinical lesions until day 28 p.i. In both un-
treated and treated infected eyes, Acanthamoeba persistencewas
established on day 28p.i. by culture, PCR and histology.
For the first time, to our knowledge, corneal voriconazole con-
centrations were measured in non-infected eyes of voriconazole-
treated AK rats to suitably document concentrations during
infection. At the end of a 3-day hourly topical instillation se-
quence, cornea concentrations were in the same range as the
estimated amoebicidal IC90 and were markedly reduced after
switching to instillations every 2h. While using 1000%more con-
centrated eye drops, resulting cornea concentrations were not
proportionally increased compared with values obtained in nor-
mal and Paecilomyces lilacinus keratitis rabbits, respectively,19
and appeared to depend more on instillation frequency than on
voriconazole dose, consistent with an absence of the corneal
‘reservoir’ effect, as reported in human aqueous humour, and
reminiscent of the need for high instillation frequency to main-
tain voriconazole corneal concentrations above the MIC90 for
most fungal species.20 Accordingly, corneal voriconazole con-
centrations were found to be equivalent, after a regimen of eye
drops every 2 h, to that in the aqueous humour of humans,20
and elevated aqueous humour concentrations were rapidly ob-
tained after eye instillation in humans.18 In topically treated
rats, plasma concentrations were close to those in healthy
horses21 and presumably lower than those associated with ad-
verse side effects in humans.22 Owing to ethical constraints,
one eye of each rat was infected. Thus, voriconazole was quanti-
fied in non-infected cornea since infected corneas were used for
microbiological/histological assessments. Since concentrations
in infected corneas likely exceed those in non-infected ones,
this may represent a limitation for extrapolating our results to
infected corneas.12
Reminiscent of reports of aqueous humour in humans, in which
voriconazole concentration was half of that in plasma 3h after oral
administration,23 the oral regimen resulted in cornea concentrations
Table 2. Evaluation of the clinical efficacy of eye-drop and oral voriconazole treatments against A. polyphaga rat keratitis symptoms
Group of rats Grade 0a Grade 1a Grade 2a Grade 3a Grade worseningb
Untreated (n"10) 1/10 1/10 4/10 4/10 9/10
Eye-drop voriconazole (n"10) 0/10 4/10 5/10 1/10 1/10*
Oral voriconazole (n"9) 0/9 1/9 5/9 3/9 4/9
aGrades were evaluated at day 14 p.i.
bRatios of animals with grade worsening from day 7 to day 14 p.i.
*P,0.01 compared with the untreated group.
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lower than the IC90. Unwanted side effects may, however, prevent
the use of high systemic doses of voriconazole, which also exhibits
high inter- and intra-individual variabilities in residual concentrations
andnon-linear pharmacokinetic characteristics.22
The present data seem to underline the need for high voricon-
azole corneal concentrations for AK therapy. Therefore, further
studies are necessary to investigate other routes of administration
to achieve higher corneal concentrations and to study the cystici-
dal effect of voriconazole on different Acanthamoeba strains and
its efficacy in associationwith other drugs.
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